Program Schedule — Atlantic Standard Time (UTC-4)
1:00 PM – 1:30 PM — Registration and Lunch Buffet
1:30 PM – 3:00 PM — Educational Meeting
Location
Puerto Rico Convention Center
100 Convention Boulevard
San Juan, Puerto Rico
Phone: +1 (787) 641-7722
Meeting Room
Ballroom A (Level 3)
No registration fee is charged for this event. For the in-person symposium in San Juan, preregistration is required as seating is limited.
Faculty Nicoletta Colombo, MD
Director, Gynecologic Oncology Program
European Institute of Oncology IRCCS
University of Milano-Bicocca
Milan, Italy
Gottfried E Konecny, MD
Professor of Medicine and Ob/Gyn
Director, Medical Gynecologic Oncology
Division of Hematology and Oncology
David Geffen School of Medicine
University of California, Los Angeles
Los Angeles, California
Additional faculty to be announced.
Moderator Shannon N Westin, MD, MPH, FASCO, FACOG
Professor
Medical Director, Gynecologic Oncology Center
Director, Early Drug Development
Department of Gynecologic Oncology and Reproductive Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Corcept Therapeutics Inc, and Merck.
Program Schedule — Atlantic Standard Time (UTC-4)
1:00 PM – 1:30 PM — Registration and Lunch Buffet
1:30 PM – 3:00 PM — Educational Meeting
MODULE 1: Current Role of PARP Inhibitors in Therapy for Advanced Ovarian Cancer (OC)
Optimal approaches to biomarker testing for patients with newly diagnosed advanced OC; significance of somatic and germline BRCA mutations and homologous recombination deficiency status in treatment decision-making
Long-term findings, including overall survival (OS) outcomes, with olaparib, olaparib/bevacizumab and niraparib maintenance for patients with newly diagnosed OC
Clinical, biological and practical factors affecting the selection of up-front olaparib, olaparib/bevacizumab and niraparib maintenance
Ongoing Phase III studies, such as the MONO-OLA1 and NRG-GY036 trials, further exploring up-front PARP inhibitor maintenance therapy
Current clinical utility, if any, of PARP inhibitors for patients with relapsed/refractory OC, including among those who have experienced disease progression after prior PARP inhibitor therapy
Incidence and clinical relevance of FRα expression in OC; optimal approaches to and timing of FRα testing
Long-term data, including OS findings, with mirvetuximab soravtansine for patients with FRα-positive, platinum-resistant OC from the Phase III MIRASOL trial
FDA approval of mirvetuximab soravtansine for FRα-positive, platinum-resistant OC; implications for biomarker assessment and current management
Key findings from the Phase II PICCOLO trial of mirvetuximab soravtansine for FRα-positive, platinum-sensitive OC; current and potential clinical role in this setting
Design, eligibility criteria and key efficacy and safety endpoints of the Phase III GLORIOSA trial evaluating mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with FRα-positive OC whose disease has not progressed after second-line platinum-based chemotherapy and bevacizumab
Mechanistic similarities and differences between investigational FRα-targeted antibody-drug conjugates, such as rinatabart sesutecan (Rina-S) and AZD5335, and mirvetuximab soravtansine
Early data, if available, and ongoing evaluation of Rina-S and AZD5335 for FRα-expressing, platinum-resistant OC, such as from the TREVI-OC-01, FONTANA and RAINFOL-02 trials
MODULE 3: Promising Novel Agents and Strategies Nearing the Clinic for Advanced OC Treatment
Mechanism of antitumor activity of the selective glucocorticoid receptor modulator relacorilant and rationale for its evaluation in treatment for advanced OC
Recently published efficacy and safety findings from the Phase III ROSELLA study of relacorilant with nab paclitaxel versus nab paclitaxel alone for patients with platinum-resistant advanced OC
Tolerability profile of relacorilant/nab paclitaxel in the ROSELLA study; relative contributions of each agent in terms of toxicities
Ongoing FDA review of relacorilant for advanced OC and its potential role in clinical practice
Recently presented data from the Phase III KEYNOTE-B96 study evaluating the addition of pembrolizumab to chemotherapy with or without bevacizumab for patients with platinum-resistant recurrent OC; related FDA approval
Potential clinical role of pembrolizumab in therapy for patients with platinum-resistant recurrent OC
Other promising novel agents and strategies nearing the clinic for patients with advanced OC
MODULE 4: Diagnosis and Management of Adverse Events Associated with Commonly Employed Therapies for Advanced OC
Spectrum, incidence and severity of common class- and agent-specific toxicities associated with PARP inhibitors for patients with OC
Optimal mitigation, monitoring and management of common PARP inhibitor-related toxicities
Reported risk of long-term, serious side effects, such as acute myeloid leukemia/myelodysplastic syndromes, with PARP inhibitor therapy
Pathogenesis and incidence of ocular adverse reactions associated with mirvetuximab soravtansine
Recommended approaches to monitoring, preventing and ameliorating mirvetuximab soravtansine-associated ocular toxicities
Spectrum, frequency, severity and management of other side effects, such as peripheral neuropathy, gastrointestinal toxicities, fatigue and pneumonitis, in patients receiving mirvetuximab soravtansine
Target Audience
This activity is intended for gynecologic oncologists, medical oncologists, gynecologists and other healthcare providers involved in the treatment of gynecologic cancers.
Learning Objectives
Upon completion of this activity, participants should be able to
Understand available clinical research findings with PARP inhibitors as maintenance therapy after first-line platinum-based chemotherapy for advanced ovarian cancer (OC), and appropriately counsel patients regarding personalized treatment recommendations.
Evaluate published research with PARP inhibitors in combination with other systemic therapies, and consider the current and future clinical and research implications of these findings in OC management.
Appraise biological and patient- and treatment-related factors to individualize the selection and sequencing of therapy for platinum-sensitive and platinum-resistant recurrent OC.
Recognize the rationale for targeting folate receptor alpha (FRα) in OC, and understand the mechanism of action of and available research findings with FRα-directed antibody-drug conjugates.
Appreciate available and emerging clinical research findings with anti-PD-1/PD-L1 antibodies in combination with chemotherapy for patients with platinum-resistant OC, and consider the potential role of this novel therapeutic strategy.
Understand the biological justification for the evaluation of selective glucocorticoid receptor modulators in combination with chemotherapy for patients with platinum-resistant OC, and recall available Phase III findings with this novel approach.
Recognize adverse events associated with therapeutic approaches commonly employed for OC, and implement strategies to educate patients and manage complications.
Describe the scientific justification for, published research data with and current research studies of novel agents and strategies for OC, and effectively prioritize clinical trial opportunities for eligible patients.
CME Credit Form
A CME credit link will be given to each participant as part of the meeting course materials.
Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.
Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided.
FACULTY — Dr Konecny has no relevant conflicts of interest to disclose. The following faculty reported relevant financial relationships with ineligible entities:
MODERATOR Dr Westin — Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Caris Life Sciences, Corcept Therapeutics Inc, Daiichi Sankyo Inc, Eisai Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, GSK, Immunocore, ImmunoGen Inc, Incyte Corporation, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Mereo BioPharma, NGM Biopharmaceuticals, Nuvectis Pharma Inc, Ottimo Pharma, Pfizer Inc, pharmaand GmbH, PMV Pharma, Seagen Inc, Verastem Inc, Zentalis Pharmaceuticals, ZielBio; Contracted Research: AstraZeneca Pharmaceuticals LP, Avenge Bio, Bayer HealthCare Pharmaceuticals, Bio-Path Holdings Inc, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, GSK, Jazz Pharmaceuticals, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Mereo BioPharma, Novartis, Nuvectis Pharma Inc, pharmaand GmbH, Pfizer Inc, Verastem Inc, Zentalis Pharmaceuticals.
EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.
RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Corcept Therapeutics Inc, and Merck.
Puerto Rico Convention Center
100 Convention Boulevard
San Juan, Puerto Rico 00907
Phone: +1 (787) 641-7722
Meeting Room
Ballroom A (Level 3)
Directions
The Puerto Rico Convention Center is the main venue for the 2026 SGO Annual Meeting on Women’s Cancer.
This activity is intended for gynecologic oncologists, medical oncologists, gynecologists and other healthcare providers involved in the treatment of gynecologic cancers.
There is no registration fee for this event. For the in-person symposium in San Juan, preregistration is required as seating is limited.
NOTICE Registration for this event is independent of registration for the 2026 SGO Annual Meeting on Women’s Cancer.
IN-PERSON registration for clinicians in practice/healthcare professionals
I am a practicing physician, fellow, nurse or other healthcare provider involved in the treatment of cancer.
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk before the start of the meeting. We cannot guarantee seating after the start of the program.
Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.
Research To Practice fully complies with the legal requirements of the ADA. If you require any physical, dietary or other accommodations, please call us at (800) 233-6153 before the event.
If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153.
